measles + mumps + rubella + Japanese encephalitis vaccine

This refers to the concurrent administration of the measles-mumps-rubella (MMR) vaccine and the live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV). This specific co-administration regimen was evaluated in a Phase 4 clinical trial sponsored by PATH in the Philippines to assess the safety and immunogenicity of simultaneous versus sequential vaccination in infants aged 9-12 months. The MMR vaccine used in the study was manufactured by GSK and contained the Schwarz measles, RIT 4385 mumps, and Wistar RA 27/3 rubella strains. The CD-JEV component was manufactured by the Chengdu Institute of Biological Products. The trial demonstrated that concurrent administration is safe and non-inferior to sequential administration, with no significant differences in immunogenicity for any of the four viral antigens (measles, mumps, rubella, or Japanese encephalitis virus).

Brand names

CD-JEV

Other names

MMR + CD-JEVConcurrent CD-JEV and MMR Vaccine